Crinetics Pharmaceuticals (CRNX) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts CRNX Hot Sheet
Join SI Premium – FREE
Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($1.04), $0.11 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $360 thousand versus the consensus estimate of $137.5 thousand.
For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flagstar Financial, Inc. (FLG) Misses Q2 EPS by 2c
- AppFolio (APPF) Tops Q2 EPS by 2c ; Offers Guidance
- Boston Beer Co. (SAM) Misses Q2 EPS by 131c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
